FT836

Relapsed/Refractory AML and B-cell Malignancies

Phase 1Active

Key Facts

Indication
Relapsed/Refractory AML and B-cell Malignancies
Phase
Phase 1
Status
Active
Company

About Fate Therapeutics

Fate Therapeutics is on a mission to deliver 'Better Cells for Better Therapies®' by leveraging its industry-leading induced pluripotent stem cell (iPSC) platform to create off-the-shelf, uniformly engineered cell products. The company has established a broad clinical pipeline targeting hematologic malignancies, solid tumors, and autoimmune disorders, with multiple programs in Phase 1/2 development. Its core strategy is to disrupt the cell therapy paradigm by moving from bespoke, patient-specific manufacturing to a scalable, industrialized model that promises greater consistency, lower cost, and immediate patient access.

View full company profile